Corporate Banner
Satellite Banner
Technology Networks Header
Thursday, June 20, 2013
Technology Networks
 
Register | Sign in
Home Page>Posters

  Posters

Promega’s Multiplexed Luciferase Reporter and Cell Viability Assays performed on the PHERAstar
Tracy Worzella and Brad Larson

By multiplexing a reporter assay (EnduRen™, ViviRen™) with a cell viability assay (CellTiter-Glo®), it is possible to determine if reporter response variations are due to changes in cell number and health. In this poster, we demonstrate the combination of several Promega cell-based assays multiplexed in both low-volume 384- and 1536-well plate formats using the BMG LABTECH PHERAstar microplate reader to record luminescence.

More Information
Metabolic Stability and Clearance of Pharmaceutical Chemicals in Pre-Pooled Cryopreserved Hepatocytes
Aruna Koganti, Nicola J. Hewitt, Wei Zhang, Michael Cheseborough, Christopher M. Terrell, Paul M. Silber and Charles B. Jensen

Cryopreserved hepatocytes express both phase I and phase II enzymes and facilitate early evaluation of the metabolic stability of pharmaceuticals. Availability of pre-pooled cryopreserved hepatocytes further enhances the utility of this model by reducing donor to donor variability. In this study, the metabolic stability of 29 pharmaceutical compounds were evaluated in pre-pooled cryopreserved human hepatocytes.

More Information
CYP4F Enzymes are the Major Enzymes in Human Liver Microsomes that Catalyze the O-Demethylation of the Antiparasitic Prodrug DB289
Greg Loewen, Michael Zhuo Wang, Janelle Saulter, Etsuko Usuki, Yen-Ling Cheung, Michael Hall, Arlene Bridges, Oliver Parkinson, Chad Stephens, James Allen, Darryl Zeldin, David Boykin, Richard Tidwell, Mary Paine, James Hall and Andrew Parkinson

DB289 is a prodrug that is converted by several steps to the active metabolite DB75. DB289 exhibits enhanced oral efficacy and reduced acute toxicity over DB75, an aromatic dicationic compound that is effective against a broad range of pathogens in vitro including African trypanosomiasis (African sleeping sickness). This reaction phenotyping study aimed to identify the enzymes responsible for oxidative O-demethylation; the first step in this conversion to DB75.

More Information
Effects of Gender, age and Ethnicity on Human Cytochrome P450 Activity
Lisa Collins, L. Anne Dwyer, Zell Woodworth, Tiffin Ramsey, Clayton Otwell, Chad Pope, Stephanie Helmstetter, Terry Graves, Josh Snyder, Jason Barricklow and Andrew Parkinson

The expression of CYP enzymes is influenced by both endogenous and exogenous factors. The aim of this analysis was to evaluate whether the age, gender, or ethnicity of the donor should influence the selection of human liver microsomes for drug metabolism studies, as well as whether cigarette smoking and alcohol consumption are reliable indicators of elevated CYP1A2 and CYP2E1 activity, respectively.

More Information
Alfentanil N-deakylation: Monitoring the Formation of N-phenylpropionamide (AMX) to Determine CYP3A4 Activity in Vitro
Phyllis Yerino, Paul Toren and Andrew Parkinson

Alfentanil is a synthetic analgesic cleared exclusively by hepatic metabolism. Due to the highly linear correlation between alfentanil systemic clearance and CYP3A4 activity, as well as the direct pharmacologic effects on pupil size, it has been used as a non-invasive metabolic probe for CYP3A4 activity in vivo. AMX is a direct metabolite of alfentanil, evaluated in this study for its potential to measure CYP3A4 activity in vitro.

More Information
Kinetic Constants and Sample-to-Sample Variation in the Rate of Metabolism of two or more Substrates for Human Liver Microsomal CYP1A2, CYP2B6, CYP2C8, CYP2D6 and CYP3A4/5
Zell Woodworth, L. Anne Dwyer, Lisa Collins, Terry Graves, Stephanie Helmstetter, Brian Ogilvie, Clayton Otwell, Chad Pope, Tiffin Ramsey, Phyllis Yerino and Andrew Parkinson

Marker substrates for certain CYPs have changed for several reasons, including the need for improved selectivity and sensitivity, reliable substrates for LC/MS/MS analysis, and substrates that provide greater repeatability. The objectives of this study were to compare sample-to-sample variation in cytochrome P450 enzymatic rates between two or more CYP-specific substrates and to determine Michaelis-Menten kinetic constants for these same reactions using a pool of human liver microsomes.

More Information
Spectrophotometric Determination of Terbinafine Hydrochloride in Bulk Drug and Pharmaceutical Formulation
Chaudhari V. P. Kulkarni M. S. Kuchekar B. S. and Chaudharik. P.

A simple, economical accurate and reproducible U.V. spectrophotometric method for the determination of Terbinafine Hydrochloride in both pure and pharmaceutical dosage form has been developed. Terbinafine Hydrochloride shows maximum absorbance at 223 nm with molar absorptivity of 9.378 x 103 lit/mole/cm. Beer’s law was obeyed in the concentration range of 0.6-4.2 ug/ml. The results of analysis were validated statistically and by recovery studies.

More Information
High Throughput High Content Screening using a Multiwavelength Microplate Cytometer
Sarah Payne, Paul Wylie and Wayne Bowen

The Acumen eX3, a multiwavelength microplate cytometer, offers 405, 488 and 633 nm laser excitations in one instrument. This advancement significantly extends the range of fluorescent reagents that can be combined in multicolour, multiplexed assays over a wavelength range for excitation that is similar to that of white light source instrumentation. Thus, it permits seamless transfer of high content assay protocols, developed using CCD-based imaging devices, onto the Acumen eX3 for screening.

More Information
An Ultra-High Throughput Approach to High Content Screening in 1536-Well Format
Yan Wang, Robert L. Davis and Wayne Bowen

The Acumen Explorer combines the object-recognition capabilities of image-based systems with read speeds similar to that of bulk readers. Here, we demonstrate the powerful integration of an Acumen Explorer with the Kalypsys® Integrated Screening System, with capability to screen > 300,000 wells per day of high content data.

More Information
<< 4 5 6 7 8 9 10 >>
Showing Results 61 - 70 of 99
Scientific News
A Toxicokinetic Model for Thiamethoxam in Rats: Implications for Higher-Tier Risk Assessment
Toxicokinetic models are promising for wildlife risk assessments, but good understanding of feeding patterns is needed for accurate estimation of chronic risk.
IBN Creates Unlimited Source of Human Kidney Cells
Applications include in vitro toxicology, disease models & regenerative medicine.
Researchers Identify Novel Class of Drugs for Prostate Cancers
A new study on prostate cancer describes a novel class of drugs that interrupts critical signaling needed for prostate cancer cells to grow.
Molecular Modelling to Help Create Better, Safer Drugs
How our bodies break down the common drugs ibuprofen, diclofenac and warfarin is the subject of a new study from the University of Bristol.
Computer Simulations Reveal the Energy Landscape of Ion Channels
A team of researchers have investigated the opening and closing mechanisms of these channels: for the first time the full energy landscape of such a large protein could be calculated.
Schmidt Fund Awards to Advance Innovations in Drug Therapy and Search for Planets
Two Princeton University research projects have been selected to receive grants from Princeton's Eric and Wendy Schmidt Transformative Technology Fund.
Side Effects to be Discovered more Quickly, Leading to Safer Prescribing
BMJ Learning has teamed up with the MHRA to launch a new, interactive and multimedia learning module on pharmacovigilance.
Researchers Discover New Therapy for Fragile X Chromosome Syndrome
Researchers at the University of the Basque Country (UPV/EHU) and the Achucarro neurosciences centre have discovered a new therapy for the fragile X chromosome syndrome.
Onconova Announces Positive Data of Oral Rigosertib in Advanced Head and Neck Cancer
Oral rigosertib progresses to phase 2 clinical trial in squamous cell head and neck cancers.
Startup Launched from Georgia Tech-Emory University Research Receives $7.9 Million
Clearside Biomedical, Inc. has received $7.9 million in funding to continue drug and technology development for treatment of ocular diseases.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv
Go to ePosters.net